Palisade Bio, Inc.PALI
What Palisade Bio, Inc. does.
We are a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 (“PDE4”) inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. Our lead clinical product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (“IBD”), including ulcerative colitis (“UC”) and Crohn’s disease (“CD”).
We are committed to advancing a next generation of once daily, oral PDE4 inhibitor prodrugs to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases.
• advancing our lead clinical product candidate, PALI-2108, towards a Phase 2 clinical study in UC designed to evaluate clinical remission response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing maintenance of remission;
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $13,520 | — | $0 | $250,000 | $0 | $0 |
| Net income | -$10.3M | -$26.6M | -$14.3M | -$12.3M | -$14.4M | -$16.8M |
| Free cash flow | -$4.8M | -$14.8M | -$13.4M | -$11.1M | -$12.2M | — |
More on PALI.
- Palisade Bio, Inc. summary
- Palisade Bio, Inc. financial statements
- Palisade Bio, Inc. key metrics
- Palisade Bio, Inc. health scores and style box
- Palisade Bio, Inc. earnings
- Palisade Bio, Inc. dividends
- Palisade Bio, Inc. valuation
- Palisade Bio, Inc. ownership and insiders
- Palisade Bio, Inc. peers
Figures from Palisade Bio, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.